InsiderSignalSign in

← Insider buys

ACET

Adicet Bio, Inc. · Healthcare

Insiders bought $1.6M of Adicet Bio, Inc. in the last 12 months

1 insider bought on 1 day.

$1.6MBought, 12 mo

$675KSold, 12 mo

$42.8MMarket cap

ACET over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

Ra Capital Management, L.P.10% owner · 1 day$1.6M

ACET after insider buys

3 months after each buy, from the first price a copier could get.

−26.8%Average

−31.2 ptsVs S&P 500

1 of 4Higher

4 buys since 2023 with 3 months of prices.

Every filing

92 insider filings since 2016, newest first

Ra Capital Management, L.P. · 10% owner

$1.6M+23.0%Apr 13

Orbimed Advisors LLC · 10% owner

$675K−10.0%Apr 9

Orbimed Advisors LLC · 10% owner

$5.0M+207.0%Oct 10

Orbimed Advisors LLC · Director and 10% owner

$7.5M−1607.0%Jan 26

Carl L Gordon · Director and 10% owner

$7.5M−1607.0%Jan 26

Carl L Gordon · Director and 10% owner

Orbimed Advisors LLC · Director and 10% owner

Don Healey · CTO

$34K−6.0%Feb 17

Don Healey · CTO

$83K−13.0%Feb 14

Blake Aftab · Chief Scientific Officer

$146K−20.0%Nov 15

Chen Schor · President and CEO

$811K−22.0%Nov 15

Chen Schor · President and CEO

$571K−14.0%Nov 9

Chen Schor · President and CEO

$457K−11.0%Nov 4

Blake Aftab · Chief Scientific Officer

$131K−19.0%Oct 21

Blake Aftab · Chief Scientific Officer

$25K−4.0%Oct 14

Chen Schor · President and CEO

$1.3M−23.0%Sep 13

Blake Aftab · Chief Scientific Officer

$125K−15.0%Aug 5

Blake Aftab · Chief Scientific Officer

$116K−13.0%Aug 3

Francesco Galimi · SVP and Chief Medical Officer

$328K−21.0%Apr 5

Aya Jakobovits · Director

$56K−1.0%Mar 11

Aya Jakobovits · Director

$59K−1.0%Feb 17

Chen Schor · President and CEO

$173K−15.0%Jun 21

Aya Jakobovits · Director

$43K−1.0%Jun 17

Chen Schor · President and CEO

$198K−14.0%Jun 7

Chen Schor · President and CEO

$221K−13.0%May 21

Aya Jakobovits · Director

$113K−1.0%May 20

Aya Jakobovits · Director

$132K−1.0%May 14

Chen Schor · President and CEO

$234K−12.0%May 7

Chen Schor · President and CEO

$198K−14.0%Apr 22

Chen Schor · President and CEO

$215K−13.0%Apr 8

Chen Schor · President and CEO

$253K−100.0%Apr 1

Chen Schor · President and CEO

$212K−12.0%Apr 1

Albert L Eilender · Chair

$35K−4.0%Sep 7

Charles John Alaimo · SVP

$56K−17.0%Sep 6

Salvatore J Guccione Sr · President and CEO

$103K−4.0%Sep 6

Albert L Eilender · Chair

$100K−3.0%Sep 6

Douglas A Roth · SVP and CFO

$68K−6.0%Sep 6

Frank Debenedittis · SVP

$32K−3.0%Sep 6

Walter J Kaczmarek III · COO

$28K−4.0%Sep 5

Walter J Kaczmarek III · COO

$117K−13.0%Aug 3

Salvatore J Guccione Sr · President and CEO

$113K−4.0%Jul 7

Albert L Eilender · Chair

$99K−3.0%Jul 7

Frank Debenedittis · SVP

$32K−3.0%Jul 7

Charles John Alaimo · SVP

$40K−15.0%Jul 7

Douglas A Roth · SVP and CFO

$79K−6.0%Jul 7

Steven Rogers · SVP and General Counsel

$35K−11.0%Jul 7

Frank Debenedittis · SVP

$54K−4.0%Mar 10

Charles John Alaimo · SVP

$81K−17.0%Mar 9

Raymond Bartone · SVP

$108K−13.0%Dec 9

Douglas A Roth · SVP and CFO

$105K−6.0%Dec 9

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.